SUPPORT LINE

0300 111 1234

Message

EU e-Privacy Directive

This website uses cookies to manage authentication, navigation, and other functions. By using our website, you agree that we can place these types of cookies on your device.

View e-Privacy Directive Documents

You have declined cookies. This decision can be reversed.

Tolvaptan Trial Results Announced

User Rating: 1 / 5

Star ActiveStar InactiveStar InactiveStar InactiveStar Inactive
 

At the American Society of Nephrology (ASN) meeting on 3 November 2012, Dr Vicente Torrres from the Mayo Clinic, together with research collaborators, reported the results of a 3 year global study known as TEMPO - Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease Outcomes.

Over 1400 ADPKD patients worldwide were randomly assigned to receive Tolvaptan or a placebo. Tolvaptan was shown to reduce the rate of increase in Total Kidney Volume (TKV), lessen symptoms such as pain and reduce the rate of kidney function decline, compared with the placebo. However patients who received Tolvaptan had more side effects related to thirst and frequent urination and some patients had raised liver-enzyme levels.

Tolvaptan was developed by Otsuka in Japan and, if approved by the medical regulatory agencies, could become the first commercially available drug treatment to slow down the rate of disease progression for ADPKD patients. The reduction in size and reduced pain may alos be good arguments for treatment in some patients with otherwise kidney function.

We will prepare a release on the implications for patients in the UK, as Tolvaptan is not currently licensed for ADPKD and we do not know whether it will be approved here.

Click here to read the Official News Release from Otsuka Pharmaceutical Company

Click here to view the full text of study results in the New England Journal of Medicine

Print Email

0
0
0
s2sdefault

Latest Tweets

PKD Charity is a Member of

  • Fundraising Regulator Website
  • Visit The Information Standard website
  • Visit PKD International website
  • Visit Ciliopathy Alliance website
  • Visit the Genetic Alliance UK website
  • Rare Disease UK Website
  • National Voices Website
  • Specialised Healthcare Alliance Website
  • FEDERG Website
  • Visit EURORDIS website